Literature DB >> 29914792

Simvastatin and bone marrow-derived mesenchymal stem cells (BMSCs) affects serum IgE and lung cytokines levels in sensitized mice.

Maryam Mohammadian1, Hamid Reza Sadeghipour2, Gila Pirzad Jahromi3, Mahvash Jafari4, Amir Kavian Nejad5, Safoura Khamse6, Mohammad Hossein Boskabady7.   

Abstract

INTRODUCTION: The effects of bone marrow-derived mesenchymal stem cells (BMSCs) and simvastatin combination therapy on serum total and specific IgE levels and lung IL-13 and TGF-β levels in sensitized mouse were examined.
MATERIAL AND METHODS: Control (n = 5), Sensitized (S), (n = 5), S + BMSC (n = 6), S + simvastatin (n = 6) and S + BMSC + simvastatin (n = 4) groups of BALB/c mice were studied. Mice were sensitized by ovalbumin. Sensitized mice were treated with a single intravenous injection of BMSCs (1 × 106) or daily intraperitoneal injection of simvastatin (40 mg/kg) or both BMSCs and simvastatin on the last week of challenge. Serum total and ovalbumin specific IgE levels as well as IL-13 and TGF-β levels in broncho-alveolar lavage (BAL) fluid were evaluated.
RESULTS: Serum total and specific IgE levels as well as lung IL-13 and TGF-β levels were significantly increased in S group compared to control group (P < 0.001 for all cases). Treatment with BMSCs, simvastatin and their combination significantly decreased serum total and specific IgE levels (P < 0.05 to P < 0.01). However, IL-13 and TGF-β levels were significantly decreased by BMSCs and BMSC + simvastatin combination therapy (P < 0.05 for all cases). The effect of simvastatin and BMSCs combination therapy on serum specific IgE levels as well as lung IL-13 and TGF-β levels were significantly higher than the effect of BMSCs and simvastatin alone (P < 0.001 for IL-13 and P < 0.01 for other cases).
CONCLUSIONS: Simvastatin and BMSCs combination therapy affects serum IgE as well as lung IL-13 and TGFβ levels more than BMSC therapy and simvastatin therapy alone which may be due to increased BMSCs migration into the lung tissue.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Asthma; Cell therapy; Cytokine; Inflammation

Mesh:

Substances:

Year:  2018        PMID: 29914792     DOI: 10.1016/j.cyto.2018.06.016

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  3 in total

Review 1.  Chronic obstructive pulmonary disease and asthma: mesenchymal stem cells and their extracellular vesicles as potential therapeutic tools.

Authors:  Hossein Abbaszadeh; Farzaneh Ghorbani; Sanaz Abbaspour-Aghdam; Amin Kamrani; Hamed Valizadeh; Mehdi Nadiri; Armin Sadeghi; Karim Shamsasenjan; Farhad Jadidi-Niaragh; Leila Roshangar; Majid Ahmadi
Journal:  Stem Cell Res Ther       Date:  2022-06-20       Impact factor: 8.079

Review 2.  Effects of statins on the biological features of mesenchymal stem cells and therapeutic implications.

Authors:  Armita Mahdavi Gorabi; Nasim Kiaie; Matteo Pirro; Vanessa Bianconi; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Heart Fail Rev       Date:  2021-09       Impact factor: 4.214

3.  Protective effects of ascorbic acid and calcitriol combination on airway remodelling in ovalbumin-induced chronic asthma.

Authors:  Farzaneh Kianian; Seyed Morteza Karimian; Mehri Kadkhodaee; Nasrin Takzaree; Behjat Seifi; Hamid Reza Sadeghipour
Journal:  Pharm Biol       Date:  2020-12       Impact factor: 3.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.